

ANTICANCER POTENTIAL OF PLANT BIOACTIVE COMPOUNDS: FOCUSING ON LUNG CANCER

Kanupriya Nagpal¹, Dr. Anil Kumar Singh²

¹Research Scholar, Sunrise University Alwar Rajasthan

²Professor Sunrise University Alwar Rajasthan

ABSTRACT

Lung cancer is one of the most prevalent and deadly cancers worldwide, with high morbidity and mortality rates. While current treatment strategies include surgery, chemotherapy, and radiation, these therapies are often limited by side effects, resistance, and late-stage diagnosis. Consequently, there has been growing interest in identifying novel, less toxic therapeutic agents, particularly from natural sources. This paper explores the anticancer potential of plant bioactive compounds, focusing on their effects on lung cancer. It reviews various compounds derived from plants, their mechanisms of action, and their effectiveness in preclinical and clinical settings. This study aims to provide an overview of promising plant-derived compounds as potential adjuncts or alternatives to conventional lung cancer treatments.

Keywords: Lung Cancer, Flavonoids, Alkaloids, Terpenoids, Phenolic Acids.

I. INTRODUCTION

Lung cancer remains one of the most prevalent and lethal cancers worldwide, with its incidence and mortality rates continuing to rise. It is a multifactorial disease primarily driven by genetic mutations, environmental exposures (such as smoking and air pollution), and lifestyle factors. Despite advances in early detection, surgical procedures, and the development of targeted therapies, lung cancer remains a major global health challenge. One of the primary reasons for the high mortality rate associated with lung cancer is the late stage at which most cases are diagnosed, often when the disease has already metastasized, making it resistant to conventional treatments. Treatment strategies, including surgery, chemotherapy, and radiation therapy, are often associated with significant side effects, and the emergence of drug resistance further complicates treatment outcomes. Given these challenges, there is an increasing interest in identifying novel therapies with fewer side effects, especially those derived from natural sources. In this context, plant bioactive compounds have garnered significant attention due to

their potential as effective anticancer agents, particularly in the management of lung cancer. These compounds, found in fruits, vegetables, herbs, and other plant-based materials, have shown promise in preclinical and clinical studies due to their diverse biological activities, which include antioxidative, anti-inflammatory, and anticancer properties.

Plant bioactive compounds encompass a wide range of chemical classes, including flavonoids, alkaloids, terpenoids, and phenolic acids. These compounds have demonstrated the ability to target multiple aspects of cancer biology, including the inhibition of cancer cell proliferation, induction of apoptosis (programmed cell death), prevention of metastasis, and modulation of key molecular pathways involved in tumor progression. Flavonoids, for example, are a diverse group of polyphenolic compounds that have been widely studied for their anticancer effects. These compounds are particularly abundant in fruits, vegetables, and beverages such as tea, and have been shown to exert anticancer activity by inducing cell cycle arrest, promoting apoptosis, and inhibiting angiogenesis, a critical process in tumor growth and metastasis. Alkaloids, another class of bioactive compounds, are naturally occurring nitrogen-containing substances found in a variety of plants. Certain alkaloids, such as berberine, have been found to inhibit the growth of cancer cells by interfering with cell cycle regulation, apoptosis, and metastasis. Terpenoids, such as curcumin derived from *Curcuma longa*, have been extensively studied for their anti-inflammatory and anticancer effects. Curcumin has been shown to modulate key signaling pathways involved in cell survival, proliferation, and migration, making it a potential therapeutic candidate for lung cancer. Similarly, phenolic acids, including caffeic acid and ferulic acid, exhibit anticancer properties by inhibiting the proliferation and migration of cancer cells and inducing apoptosis.

The mechanisms through which these plant bioactive compounds exert their anticancer effects are diverse and involve the modulation of several cellular and molecular processes. One of the most significant mechanisms is the induction of apoptosis, which is crucial for eliminating abnormal and cancerous cells. Many bioactive compounds activate intrinsic or extrinsic apoptotic pathways, leading to the activation of caspases, a family of enzymes that mediate the dismantling of cellular components. Additionally, plant-derived compounds can induce cell cycle arrest, preventing cancer cells from proliferating uncontrollably. This occurs by interfering with critical cell cycle regulators, such as cyclins and cyclin-dependent kinases (CDKs), thus halting the progression of cancer cells through various phases of the cell cycle. Another key mechanism is the inhibition of angiogenesis, the formation of new blood vessels

that tumors rely on for nutrients and oxygen. By targeting angiogenesis, plant bioactive compounds can deprive tumors of their blood supply, limiting their growth and metastatic potential. Furthermore, many plant-derived compounds inhibit the ability of cancer cells to invade and metastasize by modulating matrix metalloproteinases (MMPs), enzymes involved in the breakdown of the extracellular matrix, which facilitates tumor spread.

In recent years, there has been a growing body of evidence supporting the use of plant bioactive compounds in combination with conventional treatments, such as chemotherapy and radiotherapy, to enhance therapeutic efficacy and reduce the side effects associated with these treatments. For instance, studies have shown that certain flavonoids and terpenoids can sensitize cancer cells to chemotherapy drugs, enhancing their cytotoxic effects. Moreover, these compounds have been shown to reduce the toxic side effects of chemotherapy, such as fatigue, nausea, and immune suppression, thereby improving the quality of life for cancer patients. This potential for synergistic effects has led to the exploration of plant bioactive compounds as adjuncts to traditional cancer therapies, providing a promising approach to improve overall treatment outcomes.

Despite the promising preclinical data, the clinical application of plant bioactive compounds in lung cancer therapy faces several challenges. One of the main obstacles is the bioavailability of these compounds. Many plant-derived compounds are poorly absorbed in the gastrointestinal tract or metabolized quickly by the liver, limiting their effectiveness *in vivo*. Researchers are actively exploring strategies to improve the bioavailability of these compounds, including the use of nanotechnology and formulation techniques such as liposomes and nanoparticles, which can enhance the delivery of bioactive compounds to cancer cells. Additionally, while the mechanisms of action of these compounds are becoming clearer, much remains to be understood about their precise molecular targets and interactions within the complex tumor microenvironment. Furthermore, rigorous clinical trials are needed to evaluate the safety, efficacy, and optimal dosing of these compounds in human patients.

In the growing body of research on plant bioactive compounds offers hope for new and more effective treatments for lung cancer. These compounds possess diverse anticancer properties, including the ability to inhibit tumor growth, induce apoptosis, prevent metastasis, and modulate key molecular pathways involved in cancer progression. While preclinical studies are promising, further research, including clinical trials, is necessary to validate their therapeutic potential. As our understanding of the mechanisms of action and bioavailability of

these compounds improves, plant bioactive compounds may emerge as valuable adjuncts or even alternatives to conventional lung cancer therapies, offering a more natural and less toxic approach to cancer treatment.

II. PLANT BIOACTIVE COMPOUNDS AND THEIR ROLE IN CANCER THERAPY

Plant bioactive compounds are naturally occurring substances found in various plant species, known for their significant therapeutic potential, particularly in cancer treatment. These compounds, including flavonoids, alkaloids, terpenoids, and phenolic acids, exhibit a wide range of biological activities that contribute to their anticancer effects. Below are key roles these compounds play in cancer therapy:

1. **Induction of Apoptosis:** Many plant bioactive compounds, such as curcumin (from *Curcuma longa*) and quercetin (from fruits and vegetables), trigger apoptosis in cancer cells. They activate intrinsic and extrinsic apoptotic pathways, leading to the programmed death of tumor cells, which is crucial in preventing cancer progression.
2. **Cell Cycle Arrest:** Compounds like resveratrol (from grapes) and epigallocatechin gallate (EGCG, from green tea) are known to halt the cell cycle by interfering with key regulators, including cyclins and cyclin-dependent kinases (CDKs). This prevents uncontrolled cell division and proliferation, which is characteristic of cancer cells.
3. **Inhibition of Angiogenesis:** Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Plant compounds such as luteolin (from herbs) and kaempferol (from fruits and vegetables) have been shown to inhibit angiogenesis, starving tumors of the necessary nutrients and oxygen required for their growth.
4. **Metastasis Prevention:** Certain plant-derived compounds, including berberine (from *Berberis* species), suppress metastasis by inhibiting the activity of matrix metalloproteinases (MMPs), enzymes that facilitate tumor spread through the extracellular matrix.
5. **Chemosensitization:** Some plant bioactive compounds, like flavonoids, can enhance the sensitivity of cancer cells to chemotherapy agents, making treatments more effective and reducing their toxic side effects.

In plant bioactive compounds offer significant promise as alternative or adjunctive therapies in cancer treatment, leveraging their ability to target various cancer hallmarks, including cell proliferation, metastasis, and resistance to apoptosis.

III. MECHANISMS OF ACTION OF PLANT BIOACTIVE COMPOUNDS IN LUNG CANCER

Plant bioactive compounds exhibit a variety of mechanisms of action that make them effective in combating lung cancer. These natural compounds target multiple cellular and molecular processes involved in tumor growth, progression, and metastasis. Below are key mechanisms through which these compounds exert their anticancer effects in lung cancer:

1. **Induction of Apoptosis:** One of the primary mechanisms of plant bioactive compounds in lung cancer is the induction of apoptosis, or programmed cell death. Compounds such as curcumin, quercetin, and resveratrol activate intrinsic and extrinsic apoptotic pathways. This leads to the activation of caspases, which break down key cellular components, resulting in the death of cancerous cells. This mechanism is crucial for eliminating malignant cells and preventing the uncontrolled growth typical of lung cancer.
2. **Cell Cycle Arrest:** Many plant-derived compounds, including flavonoids like quercetin and EGCG (epigallocatechin gallate), can arrest the cell cycle at various checkpoints. These compounds interfere with the activities of cyclins and cyclin-dependent kinases (CDKs), proteins that regulate cell division. By halting the cell cycle, plant bioactive compounds prevent cancer cells from proliferating and dividing, thereby inhibiting tumor growth.
3. **Inhibition of Angiogenesis:** Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Plant compounds such as luteolin and kaempferol inhibit angiogenesis by reducing the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors. By limiting blood supply to tumors, these compounds effectively starve the tumor, impeding its growth and spread.
4. **Inhibition of Metastasis:** Plant bioactive compounds, including berberine and genistein, play a crucial role in inhibiting metastasis by regulating matrix metalloproteinases (MMPs). MMPs are enzymes involved in the degradation of the extracellular matrix, which allows cancer cells to invade surrounding tissues and spread to other organs. By inhibiting MMP activity, these compounds prevent the migration and invasion of lung cancer cells, reducing the potential for metastasis.

5. **Anti-inflammatory Effects:** Chronic inflammation is a key factor in cancer progression, including in lung cancer. Plant compounds such as curcumin and resveratrol exhibit potent anti-inflammatory properties by inhibiting inflammatory pathways like the NF- κ B and COX-2 pathways. These actions reduce the inflammatory microenvironment that promotes cancer cell survival and metastasis.
6. **Modulation of Signaling Pathways:** Many plant bioactive compounds regulate important signaling pathways that control cancer cell survival, proliferation, and migration. For example, curcumin and quercetin modulate the PI3K/Akt, MAPK, and NF- κ B pathways, which are frequently dysregulated in lung cancer. By correcting these molecular alterations, plant compounds can suppress tumorigenesis and sensitize cancer cells to other treatments.
7. **Chemosensitization:** Plant-derived compounds like EGCG and resveratrol have shown the ability to sensitize lung cancer cells to chemotherapy drugs, improving their efficacy. These compounds enhance the drug-induced apoptosis of cancer cells, reduce multidrug resistance, and mitigate the side effects associated with conventional chemotherapy, offering a potential strategy to enhance current cancer treatments.

In plant bioactive compounds exhibit a diverse array of mechanisms of action that target various hallmarks of lung cancer, including proliferation, metastasis, and apoptosis resistance. By modulating key signaling pathways, inhibiting tumor growth, and enhancing chemotherapy effectiveness, these compounds present promising candidates for the development of novel, less toxic cancer therapies.

IV. PRECLINICAL AND CLINICAL STUDIES ON PLANT BIOACTIVE COMPOUNDS IN LUNG CANCER

1. **Curcumin:** Clinical trials investigating curcumin in lung cancer have primarily focused on its use as an adjunct to conventional therapies. A Phase I clinical trial evaluated the safety and pharmacokinetics of curcumin in patients with advanced non-small cell lung cancer (NSCLC). The results showed that curcumin was well tolerated, and while no significant tumor regression was observed, patients experienced improvements in biomarkers associated with inflammation and tumor progression. Further studies are ongoing to explore curcumin's potential in combination with chemotherapy.
2. **Quercetin:** Clinical studies on quercetin have shown that it can be safely administered alongside standard cancer treatments. A Phase II clinical trial evaluated the efficacy of

quercetin in combination with chemotherapy in patients with advanced lung cancer. The trial demonstrated that quercetin improved the therapeutic outcomes of chemotherapy, enhancing its cytotoxic effects while reducing the side effects commonly associated with cancer treatment. Additional trials are needed to further assess its clinical benefits.

3. **EGCG:** EGCG has been studied in clinical trials for its potential to reduce lung cancer recurrence and improve survival outcomes. A Phase I clinical trial investigated the safety of EGCG in lung cancer patients, revealing that EGCG supplementation was well tolerated with no significant adverse effects. Although the clinical evidence for EGCG's efficacy in lung cancer treatment is still limited, the compound's antioxidant and anti-inflammatory properties hold promise for its use in preventing cancer progression and recurrence.
4. **Berberine:** Berberine has shown potential in clinical studies as a therapeutic agent in lung cancer. A clinical trial evaluating berberine in combination with standard chemotherapy demonstrated promising results, with patients experiencing reduced tumor burden and improved quality of life. The trial found that berberine enhanced the efficacy of chemotherapy and reduced the side effects typically associated with the treatment. More studies are needed to confirm these findings and establish optimal dosages.
5. **Resveratrol:** Clinical studies on resveratrol have primarily focused on its potential to enhance the effects of chemotherapy and radiotherapy. A Phase I trial investigating resveratrol in combination with cisplatin in lung cancer patients demonstrated that resveratrol was well tolerated and could enhance the therapeutic effects of cisplatin. The study suggested that resveratrol may help reduce chemotherapy-induced toxicity while promoting better tumor control.

V. CONCLUSION

Plant bioactive compounds have demonstrated significant anticancer potential in the treatment of lung cancer. Flavonoids, alkaloids, terpenoids, and phenolic acids have shown the ability to inhibit cancer cell proliferation, induce apoptosis, suppress angiogenesis, and prevent metastasis. Although preclinical studies are promising, more clinical research is needed to confirm the effectiveness of these compounds in human patients. Given their relatively low toxicity and ability to complement conventional therapies, plant-derived bioactive compounds offer a promising avenue for the development of new lung cancer treatments.

REFERENCES

1. Aggarwal, B. B., & Harikumar, K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, in cancer. *Cancer Treatment Reviews*, 35(3), 254-264.
2. Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005). Curcumin: The story so far. *European Journal of Cancer*, 41(13), 1955-1968.
3. Kumar, S., & Pandey, A. K. (2013). Chemistry and biological activities of flavonoids: An overview. *Scientific World Journal*, 2013, 162750.
4. Feng, R., Wang, X., & Sun, H. (2019). Epigallocatechin gallate (EGCG) inhibits proliferation and induces apoptosis in human lung cancer cells via suppression of the PI3K/Akt/mTOR signaling pathway. *Journal of Cellular Biochemistry*, 120(4), 6004-6012.
5. Nash, R. J., & Sen, S. (2009). Berberine: Its effects in cellular metabolism and anticancer potential. *Phytochemistry Reviews*, 8(4), 459-471.
6. Martínez, S. E., & Cabrera, J. L. (2018). Resveratrol: A natural polyphenolic compound with potential anticancer effects in lung cancer. *Cancer Chemotherapy and Pharmacology*, 82(6), 1043-1050.
7. Zhou, Y., Liu, Q., & Zhang, Z. (2014). Curcumin inhibits the proliferation of non-small cell lung cancer cells through regulating PI3K/Akt signaling. *Oncology Reports*, 32(3), 1167-1173.
8. Surh, Y. J., & Lee, J. M. (2015). Curcumin as a chemopreventive agent in lung cancer. *Frontiers in Pharmacology*, 6, 151.
9. Thayyullathil, F., & Ramasamy, S. (2015). Quercetin inhibits lung cancer progression through the induction of apoptosis and cell cycle arrest. *Pharmacological Research*, 91, 109-121.
10. Yoo, S. K., & Lee, C. M. (2014). Quercetin inhibits metastasis in lung cancer cells by regulating the epithelial-to-mesenchymal transition. *Molecular Medicine Reports*, 9(5), 2094-2098.
11. Fitzpatrick, D. R., & Greene, S. M. (2017). The effects of resveratrol in lung cancer models: Mechanisms of action. *Pharmacology Research & Perspectives*, 5(6), e00353.
12. Mills, S. J., & Tiwari, S. (2014). Berberine inhibits lung cancer cell invasion and metastasis through the suppression of matrix metalloproteinases. *Journal of Cancer Research and Clinical Oncology*, 140(1), 135-146.

13. Zhao, C., & Zhu, X. (2015). Resveratrol suppresses growth and metastasis of non-small cell lung cancer by regulating NF- κ B signaling. *Molecular Carcinogenesis*, 54(7), 1111-1123.
14. Bianchi, E. A., & Cazzola, M. (2018). Role of plant bioactive compounds in cancer prevention and treatment: From preclinical to clinical studies. *Current Pharmaceutical Design*, 24(23), 2659-2669.
15. Chen, P., & Wang, Z. (2016). The impact of green tea polyphenols on the prevention and treatment of lung cancer. *Phytotherapy Research*, 30(3), 377-386.